Watch ACXP. Know when insiders buy.
One email the day a filing lands. Free.
ACXP
Acurx Pharmaceuticals, Inc.
1.42
+0.02 +1.43%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $7.5MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$7.5MNET CASH —52W 1.35 – 8.10SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$2.3M | −$2.3M | — | -0.53 | −$1.7M | — | — | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$1.7M | −$1.7M | — | -0.62 | −$1.4M | — | — | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$1.6M | −$1.6M | — | -0.31 | −$1.2M | — | — | Mar 12 |
| Q3 2025 · Sep 30 | — | — | — | −$2M | −$2M | — | -1.23 | −$1.9M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$2.3M | −$2.2M | — | -1.89 | −$1.7M | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$2.2M | −$2.1M | — | -2.15 | −$2.1M | — | — | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$2.8M | −$2.8M | — | -3.22 | −$2.3M | — | — | Mar 12 |
| Q3 2024 · Sep 30 | — | — | — | −$2.8M | −$2.8M | — | -3.45 | −$2.2M | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$4.1M | −$4.1M | — | -5.21 | −$2.9M | — | — | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | — | −$4.4M | — | -0.28 | −$3.1M | — | — | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | — | −$5.1M | — | -0.38 | −$4.2M | — | — | Mar 17 |
| Q3 2023 · Sep 30 | — | — | — | — | −$3.1M | — | -0.24 | −$2.1M | — | — | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$8.1M | −$8M | — | -5.32 | −$6.8M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$14.1M | −$14.1M | — | -17.45 | −$10.4M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | — | −$14.6M | — | -1.15 | −$9.8M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | — | −$12.1M | — | -1.12 | −$7.5M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | — | −$12.7M | — | -1.49 | −$5M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | — | −$4.6M | — | -0.74 | −$3.4M | — | — | — | — |
Every number comes from Acurx Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.